Search

Your search keyword '"Altomonte, Maria"' showing total 10 results
Start Over Author "Altomonte, Maria"
10 results on '"Altomonte, Maria"'

1. Effectiveness of biosimilar pegfilgrastim in patients with multiple myeloma after high-dose melphalan and autologous stem cell transplantation

Author

Martino, Massimo, Gori, Mercedes, Porto, Gaetana, Pellicano, Maria, Santoro, Ludovica, Verduci, Chiara, Canale, Filippo Antonio, Loteta, Barbara, Moscato, Tiziana, Alati, Caterina, Ieracitano, Maria Consuelo, Cuzzocrea, Amelia, Altomonte, Maria, Florenzano, Maria Teresa, Morabito, Antonella, Irrera, Giuseppe, Naso, Virginia, Pugliese, Marta, Console, Giuseppe, Ferreri, Anna, Imbalzano, Lucrezia, Tripepi, Giovanni, and Pitino, Annalisa

Published
2023
Full Text
View/download PDF

2. Correction to: Effectiveness of biosimilar pegfilgrastim in patients with multiple myeloma after high‑dose melphalan and autologous stem cell transplantation

Author

Martino, Massimo, Gori, Mercedes, Porto, Gaetana, Pellicano, Maria, Santoro, Ludovica, Verduci, Chiara, Canale, Filippo Antonio, Loteta, Barbara, Moscato, Tiziana, Alati, Caterina, Ieracitano, Maria Consuelo, Cuzzocrea, Amelia, Altomonte, Maria, Florenzano, Maria Teresa, Morabito, Antonella, Irrera, Giuseppe, Naso, Virginia, Pugliese, Marta, Console, Giuseppe, Ferreri, Anna, Imbalzano, Lucrezia, Tripepi, Giovanni, and Pitino, Annalisa

Published
2023
Full Text
View/download PDF

3. Effectiveness of biosimilar pegfilgrastim in patients with lymphoma after high-dose chemotherapy and autologous stem cell transplantation: a real-life study.

Author

Loteta, Barbara, Pitino, Annalisa, Pitea, Martina, Alati, Caterina, Tripepi, Giovanni, Mico, Maria Caterina, Pellicano, Maria, Cogliandro, Francesca, Porto, Gaetana, Policastro, Giorgia, Utano, Giovanna, Delfino, Ilaria Maria, Sgarlata, Annalisa, Scopelliti, Anna, Idato, Aurora, Laenza, Giovanni, Altomonte, Maria, D'Arrigo, Graziella, Gori, Mercedes, and Martino, Massimo

Published
2024
Full Text
View/download PDF

4. Effectiveness of CAR-T treatment toward the potential risk of second malignancies.

Author

Martino, Massimo, Porto, Gaetana, Policastro, Giorgia, Alati, Caterina, Loteta, Barbara, Micó, Maria Caterina, Argiro', Clizia, Altomonte, Maria, Moscato, Tiziana, Labate, Demetrio, Dattola, Vincenzo, Rao, Carmelo Massimiliano, Cogliandro, Francesca, Canale, Filippo Antonio, Naso, Virginia, Filippelli, Gianfranco, Iaria, Antonino, and Pitea, Martina

Subjects
TREATMENT effectiveness, TUMOR lysis syndrome, SKIN cancer, HEMATOPOIETIC stem cell transplantation
Abstract

This document provides a list of references to studies and articles related to CAR-T cell therapy for various types of lymphoma and multiple myeloma. The studies mentioned discuss the outcomes, safety, and efficacy of CAR-T cell therapies such as lisocabtagene maraleucel, axicabtagene ciloleucel, brexucabtagene autoleucel, ciltacabtagene autoleucel, and idecabtagene vicleucel. The document also includes references to studies that discuss the potential risk of secondary malignancies and other long-term effects associated with CAR-T cell therapy. [Extracted from the article]

Published
2024
Full Text
View/download PDF

6. Identifying and Managing CAR T-Cell–Mediated Toxicities: on behalf of an Italian CAR-T Multidisciplinary Team

Author

Martino, Massimo, primary, Macheda, Sebastiano, additional, Aguglia, Umberto, additional, Arcudi, Luciano, additional, Pucci, Giulia, additional, Martino, Bruno, additional, Altomonte, Maria, additional, Rossetti, Antonio Maria, additional, Cusumano, Giuseppa, additional, Russo, Letteria, additional, Imbalzano, Lucrezia, additional, Stelitano, Caterina, additional, Alati, Caterina, additional, Germano’, Jessyca, additional, Labate, Demetrio, additional, Amalfi, Vincenzo, additional, Florenzano, Maria Teresa, additional, Morabito, Antonella, additional, Borzumati, Vittoria, additional, Dattola, Vincenzo, additional, Gattuso, Caterina, additional, Moschella, Antonio, additional, Quattrone, Domenico, additional, Curmaci, Francesco, additional, Franzutti, Claudio, additional, Scappatura, Giuseppe, additional, Rao, Carmelo Massimiliano, additional, Loddo, Viviana, additional, Pontari, Antonella, additional, Pellicano’, Maria, additional, Surace, Rosangela, additional, Sanguedolce, Cristina, additional, Naso, Virginia, additional, Ferreri, Anna, additional, Irrera, Giuseppe, additional, Console, Giuseppe, additional, Moscato, Tiziana, additional, Loteta, Barbara, additional, Canale, Filippo Antonio, additional, Trimarchi, Alfonso, additional, Monteleone, Renza, additional, Said, Al Sayyad, additional, Cirrone, Frank, additional, and Bruno, Benedetto, additional

Published
2021
Full Text
View/download PDF

7. Distinctive germline expression of class I human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade

Author

Correale, Pierpaolo, primary, Saladino, Rita Emilena, additional, Giannarelli, Diana, additional, Giannicola, Rocco, additional, Agostino, Rita, additional, Staropoli, Nicoletta, additional, Strangio, Alessandra, additional, Del Giudice, Teresa, additional, Nardone, Valerio, additional, Altomonte, Maria, additional, Pastina, Pierpaolo, additional, Tini, Paolo, additional, Falzea, Antonia Consuelo, additional, Imbesi, Natale, additional, Arcati, Valentina, additional, Romeo, Giuseppa, additional, Caracciolo, Daniele, additional, Luce, Amalia, additional, Caraglia, Michele, additional, Giordano, Antonio, additional, Pirtoli, Luigi, additional, Necas, Alois, additional, Amler, Evzen, additional, Barbieri, Vito, additional, Tassone, Pierfrancesco, additional, and Tagliaferri, Pierosandro, additional

Published
2020
Full Text
View/download PDF

8. Correlation of HLA-B*35 and DRB1*11 alleles with a high risk of interstitial aseptic pneumonitis in cancer patients receiving PD-1/PDL1 immune-checkpoint blockade.

Author

Correale, Pierpaolo, primary, Saladino, Rita Emilena, additional, Bianco, Giovanna, additional, Stranges, Alessia, additional, Giannarelli, Diana, additional, Sergi, Andrea, additional, Mazzei, Maria Antonietta, additional, Giannicola, Rocco, additional, Iuliano, Eleonora, additional, Nardone, Valerio, additional, Altomonte, Maria, additional, Pastina, Pierpaolo, additional, Tini, Paolo, additional, Luce, Amalia, additional, Caracciolo, Daniele, additional, Calandruccio, Natale Daniele, additional, Caraglia, Michele, additional, Tassone, Pierfrancesco, additional, Pirtoli, Luigi, additional, and Tagliaferri, Pierosandro, additional

Published
2020
Full Text
View/download PDF

9. Identifying and managing CAR T-cell–mediated toxicities: on behalf of an Italian CAR-T multidisciplinary team

Author

Martino, Massimo, Macheda, Sebastiano, Aguglia, Umberto, Arcudi, Luciano, Pucci, Giulia, Martino, Bruno, Altomonte, Maria, Rossetti, Antonio Maria, Cusumano, Giuseppa, Russo, Letteria, Imbalzano, Lucrezia, Stelitano, Caterina, Alati, Caterina, Germano’, Jessyca, Labate, Demetrio, Amalfi, Vincenzo, Florenzano, Maria Teresa, Morabito, Antonella, Borzumati, Vittoria, Dattola, Vincenzo, Gattuso, Caterina, Moschella, Antonio, Quattrone, Domenico, Curmaci, Francesco, Franzutti, Claudio, Scappatura, Giuseppe, Rao, Carmelo Massimiliano, Loddo, Viviana, Pontari, Antonella, Pellicano’, Maria, Surace, Rosangela, Sanguedolce, Cristina, Naso, Virginia, Ferreri, Anna, Irrera, Giuseppe, Console, Giuseppe, Moscato, Tiziana, Loteta, Barbara, Canale, Filippo Antonio, Trimarchi, Alfonso, Monteleone, Renza, Al Sayyad, Said, Cirrone, Frank, and Bruno, Benedetto

Abstract

ABSTRACTIntroductionChimeric antigen receptor (CAR)-T-cell therapy is a new treatment for patients with hematologic malignancies in which other therapies have failed.Areas coveredThe review provides an overview for recognizing and managing the most acute toxicities related to CAR-T cells.Expert opinionThe development of immune-mediated toxicities is a common challenge of CAR-T therapy. The mechanism that determines this toxicity is still unclear, although an unfavorable tumor microenvironment and a pro-inflammatory state put patients at risk. The monitoring, diagnosis, and treatment of post-CAR-T toxicities must be determined and based on international guidelines and internal clinical practice. It is urgent to identify biomarkers that can identify patients at greater risk of developing complications. The adoption of consistent grading criteria is necessary to improve toxicity management strategies continually. The first-line therapy consists of supportive care and treatment with tocilizumab or corticosteroids. An early start of cytokine blockade therapies could mitigate toxicity. The plan will include cytokine release prophylaxis, a risk-adapted treatment, prevention of on-target/off-tumor effect, and a switch on/off CAR-T approach.

Published
2022
Full Text
View/download PDF

10. Evaluation of long term survival in pretreated metastatic colorectal cancer patients undergoing GOLFIG chemoimmunotherapy regimen.

Author

Correale, Pierpaolo, primary, Giannicola, Rocco, additional, Staropoli, NIcoletta, additional, Ciliberto, Domenico, additional, Azzarello, Domenico, additional, Tripepi, Giovanni, additional, Agostino, Rita Maria, additional, Strangio, Alessandra, additional, Altomonte, Maria, additional, Nesci, Antonio, additional, Francini, Guido, additional, Pastina, Pierpaolo, additional, Tassone, Pierfrancesco, additional, Pirtoli, Luigi, additional, Caporlingua, Nadia, additional, Falzea, Antonia Consuelo, additional, and Tagliaferri, Pierosandro, additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results